CRDF Q4 2018 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$78,000-57.8% YoY

Gross Profit

-$597M-765104.5% margin

Operating Income

-$4M-5261.5% margin

Net Income

-$4M-5332.1% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

-11.7%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$268,975

Balance Sheet

Total Assets

$14M

Total Liabilities

$4M

Stockholders' Equity

$10M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78,000	$185,000	-57.8%
Gross Profit	-$597M	-$198,000	-301304.8%
Operating Income	-$4M	-$4M	-8.5%
Net Income	-$4M	-$3M	-61.8%